Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Is alendronate therapy cost-effective for postmenopausal osteopenia?

Nature Clinical Practice Endocrinology & Metabolism volume 1, pages 74–75 (2005)Cite this article

boxed-textSchousboe JT et al. (2005) Cost-effectiveness of alendronate therapy for osteopenic postmenopausal women. Ann Int Med 142: 734–741

Background

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Lewiecki EM (2005) Review of guidelines for bone mineral density testing and treatment of osteoporosis. Curr Osteoporos Rep 3: 75–83

    Article  Google Scholar 

  2. Feldstein A et al. (2003) Bone mineral density measurement and treatment for osteoporosis in older individuals with fractures: a gap in evidence-based practice guideline implementation. Arch Intern Med 163: 2165–2172

    Article  Google Scholar 

  3. World Health Organization (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: report of a WHO study group. World Health Organ Tech Rep Ser 843: 1–129

  4. Miller PD et al. (2004) An approach to identifying osteopenic women at increased short-term risk of fracture. Arch Intern Med 164: 1113–1120

    Article  Google Scholar 

  5. Wainwright SA et al. (2005) Hip fracture in women without osteoporosis. J Clin Endocrinol Metab 90: 2787–2793

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Vicky Heath, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. Clinical Assistant Professor of Medicine at the University of New Mexico School of Medicine, and the Osteoporosis Director at New Mexico Clinical Research & Osteoporosis Center, Albuquerque, NM, USA

    E Michael Lewiecki

Authors
  1. E Michael Lewiecki
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to E Michael Lewiecki.

Ethics declarations

Competing interests

The author receives grant or research support from Merck, Eli Lilly, Novartis, Aventis, Amgen, Pfizer, Wyeth-Ayerst, Roche, and Procter & Gamble, and is a consultant, advisor, or speaker for Merck, Eli Lilly, Novartis, Procter & Gamble, Aventis, Roche, Wyeth-Ayerst, and Servier.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lewiecki, E. Is alendronate therapy cost-effective for postmenopausal osteopenia?. Nat Rev Endocrinol 1, 74–75 (2005). https://doi.org/10.1038/ncpendmet0052

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpendmet0052

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing